Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
ConditionHerpes Zoster
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age50+
SponsorCHA Vaccine Institute Co., Ltd.
About this trial
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.
Eligibility criteria
Qualifiers
Healthy adults aged 50 years or older
Able to understand the study procedures and provide written informed consent
Females and males of reproductive potential must agree to use medically acceptable contraception until 3 months after the last vaccination
Females of childbearing potential must have a negative pregnancy test prior to vaccination
Disqualifiers
History of herpes zoster prior to screening
History of severe allergic reaction to vaccines or vaccine components
Known immunodeficiency or immune dysfunction
Prior vaccination with varicella or herpes zoster vaccine
Trial design
Treatments tested in this trial
- Shingrix
- CVI-VZV-001
Treatment groups
135 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov